Increase in the number of clinical trials and rise in the frequency of neurodegenerative diseases are the factors augmenting the induced pluripotent stem cells market. The advantages of induced pluripotent stem cells (iPSCs) over embryonic stem cells (ESCs) such as higher rate of apoptosis and reduced risks of low-level DNA damage are making them a preferable choice.